GERN Archives - Page 3 of 7

3 minute read

Geron Announces 50% Enrollment In The Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat In Patients With Relapsed/Refractory Myelofibrosis

December 6, 9:14 AM

IMpactMF is the first and only Phase 3 clinical trial to evaluate overall survival as the primary endpoint in R/R MFAn interim analysis is expected in the first half of 2025, with a final analysis expected in the first

GERN

6 minute read

Geron IMerge Phase 3 Presentations At Upcoming ASH Annual Meeting Reinforce Significant Durability And Breadth Of Effect Of Imetelstat In Lower Risk MDS

By Benzinga Newsdesk

November 2, 9:17 AM

Subgroup analyses showed consistently higher transfusion independence (TI) response rates than placebo across different risk groups regardless of International Prognostic Scoring System (IPSS), revised IPSS (IPSS-R) or

GERN

29 minute read

Earnings

Earnings Scheduled For November 2, 2023

By Benzinga Insights

November 2, 4:56 AM

Companies Reporting Before The Bell • AudioCodes (NASDAQ:AUDC) is estimated to report quarterly earnings at $0.18 per share on revenue of $61.52 million.

AAPL

1 minute read

Earnings

Geron Earnings Preview

By Benzinga Insights

November 1, 1:02 PM

Geron (NASDAQ:GERN) is set to give its latest quarterly earnings report on Thursday, 2023-11-02. Here’s what investors need…

GERN

22 minute read

Stocks That Hit 52-Week Lows On Wednesday

By Benzinga Insights

October 4, 12:01 PM

On Wednesday, 311 stocks hit new 52-week lows.

AADI

37 minute read

Options

Stocks That Hit 52-Week Lows On Tuesday

By Benzinga Insights

October 3, 2:37 PM

On Tuesday, 647 companies set new 52-week lows.

AADI

2 minute read

Recent Pullback Buying Opportunity For Blood Cancer Firm Geron: Goldman Sachs

By Vandana Singh

September 12, 2:43 PM

Goldman Sachs has upgraded Geron Corporation (NASDAQ: GERN) to Buy from Neutral, with a p

BMY

13 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For September 12, 2023

By Benzinga Insights

September 12, 11:00 AM

Upgrades RBC Capital upgraded the previous rating for Equinox Gold Corp (AMEX:EQX) from Underperform to Sector Perform. In…

$TKO

2 minute read

Geron Announces Data Presentations From IMerge Phase 3 Evaluating Imetelstat In Lower Risk MDS At Society Of Hematologic Oncology Annual Meeting

By Happy Mohamed

September 7, 8:03 AM

Geron Corporation (NASDAQ:GERN), a late-stage clinical biopharmaceutical company, today announced poster presentations of data from IMerge, the Company's Phase 3 clinical trial evaluating its first-in-class

GERN

3 minute read

Why Macy’s Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session

By Lisa Levin

August 22, 1:49 PM

Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) shares jumped 42.8% to $5.60 after the FDA lifted clinical hold on the company’s FTX-6058 for sickle cell disease.

$APE

Feed Symbols: GERN